$XBIT
XBiotech Inc

2018 Q3 Form 10-Q Financial Statement

#000117184318007413 Filed on October 31, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M $1.660M $2.760M
YoY Change -28.92% -38.29% 66.27%
% of Gross Profit
Research & Development $3.940M $4.930M $13.69M
YoY Change -20.08% -49.56% 31.51%
% of Gross Profit
Depreciation & Amortization $620.0K $300.0K $170.0K
YoY Change 106.67% 66.67% -10.53%
% of Gross Profit
Operating Expenses $5.115M $6.593M $16.44M
YoY Change -22.42% -47.08% 36.21%
Operating Profit -$5.115M -$6.593M -$16.44M
YoY Change -22.42% -47.08%
Interest Expense $60.00K $390.0K $40.00K
YoY Change -84.62% -1400.0% -75.0%
% of Operating Profit
Other Income/Expense, Net $64.00K $388.0K $0.00
YoY Change -83.51% -1652.0% -100.0%
Pretax Income -$5.050M -$6.210M -$16.40M
YoY Change -18.68% -50.24% 37.93%
Income Tax
% Of Pretax Income
Net Earnings -$5.051M -$6.205M -$16.40M
YoY Change -18.6% -50.3% 37.91%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$141.0K -$175.3K -$504.5K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q3 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.80M $39.00M $34.30M
YoY Change -46.67% -16.67% -62.35%
Cash & Equivalents $20.85M $38.98M $34.32M
Short-Term Investments
Other Short-Term Assets $500.0K $1.300M $2.600M
YoY Change -61.54% -35.0% 30.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.31M $40.29M $36.93M
YoY Change -47.12% -17.51% -60.31%
LONG-TERM ASSETS
Property, Plant & Equipment $27.94M $30.38M $10.14M
YoY Change -8.04% 201.35% 70.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $27.94M $30.38M $30.12M
YoY Change -8.04% 3.16% 84.59%
TOTAL ASSETS
Total Short-Term Assets $21.31M $40.29M $36.93M
Total Long-Term Assets $27.94M $30.38M $30.12M
Total Assets $49.24M $70.67M $67.05M
YoY Change -30.32% -9.73% -38.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $878.0K $2.225M $4.431M
YoY Change -60.54% -50.17% -8.17%
Accrued Expenses $1.422M $1.277M $3.532M
YoY Change 11.35% -41.31% 140.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.300M $3.502M $7.963M
YoY Change -34.32% -47.27% 26.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.300M $3.502M $7.963M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.307M $3.522M $7.986M
YoY Change -34.5% -47.14% 26.6%
SHAREHOLDERS EQUITY
Retained Earnings -$231.6M -$209.3M -$183.4M
YoY Change 10.64% 25.33% 40.38%
Common Stock $278.9M $277.1M $242.4M
YoY Change 0.65% 16.03% 3.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.94M $67.15M $59.06M
YoY Change
Total Liabilities & Shareholders Equity $49.24M $70.67M $67.05M
YoY Change -30.32% -9.73% -38.69%

Cashflow Statement

Concept 2018 Q3 2017 Q3 2016 Q4
OPERATING ACTIVITIES
Net Income -$5.051M -$6.205M -$16.40M
YoY Change -18.6% -50.3% 37.91%
Depreciation, Depletion And Amortization $620.0K $300.0K $170.0K
YoY Change 106.67% 66.67% -10.53%
Cash From Operating Activities -$3.990M -$6.460M -$12.81M
YoY Change -38.24% -56.96% 19.72%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K -$260.0K -$1.960M
YoY Change -88.46% -91.82% -47.59%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$260.0K -$1.960M
YoY Change -88.46% -91.82% -47.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 50.00K 2.070M
YoY Change -100.0% -68.75%
NET CHANGE
Cash From Operating Activities -3.990M -6.460M -12.81M
Cash From Investing Activities -30.00K -260.0K -1.960M
Cash From Financing Activities 0.000 50.00K 2.070M
Net Change In Cash -4.020M -6.670M -12.70M
YoY Change -39.73% -63.01% -12.05%
FREE CASH FLOW
Cash From Operating Activities -$3.990M -$6.460M -$12.81M
Capital Expenditures -$30.00K -$260.0K -$1.960M
Free Cash Flow -$3.960M -$6.200M -$10.85M
YoY Change -36.13% -47.59% 55.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
878000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1730000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1422000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1062000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-353000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-768000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
439000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
445000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1186000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2065000
CY2018Q3 us-gaap Assets
Assets
49244000
CY2017Q4 us-gaap Assets
Assets
62972000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
21306000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
33332000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20849000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31768000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34324000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38977000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10919000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4653000
CY2018Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35819772
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35439272
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
278879000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
277492000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5023000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6495000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14612000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26574000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div></div></div></div>
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
7000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
18000
us-gaap Depreciation
Depreciation
1816000
us-gaap Depreciation
Depreciation
889000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
415000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-673000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y73D
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3000000
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-36000
CY2017Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
265000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-411000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
365000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1175000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1663000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4004000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6035000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
4500000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-853000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2207000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
360000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2254000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-11000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1108000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1294000
CY2018Q3 us-gaap Investment Income Net
InvestmentIncomeNet
100000
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
123000
us-gaap Investment Income Net
InvestmentIncomeNet
270000
us-gaap Investment Income Net
InvestmentIncomeNet
287000
CY2013Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y270D
CY2015Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P4Y
CY2018Q3 us-gaap Liabilities
Liabilities
2307000
CY2017Q4 us-gaap Liabilities
Liabilities
2810000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49244000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5115000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6593000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14886000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26553000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
79000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
118000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
197000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
590000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
186000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
558000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62972000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2300000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2792000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
201000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33319000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-114000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1151000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11421000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26842000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-5051000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-6205000
us-gaap Net Income Loss
NetIncomeLoss
-15027000
us-gaap Net Income Loss
NetIncomeLoss
-25901000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
64000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
388000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-141000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
652000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
5115000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
6593000
us-gaap Operating Expenses
OperatingExpenses
14886000
us-gaap Operating Expenses
OperatingExpenses
26553000
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
28000
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-290000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
415000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-673000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
114000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1151000
CY2018Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2017Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
457000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1564000
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1800000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31600000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
201000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
699000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
32620000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1100000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
703000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
201000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27938000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29640000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3940000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4930000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10882000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20518000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-231589000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216562000
us-gaap Share Based Compensation
ShareBasedCompensation
1186000
us-gaap Share Based Compensation
ShareBasedCompensation
1340000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
699935
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
926500
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.77
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.85
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5303624
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5449689
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
CY2017Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
13
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
145000
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
87000
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2400000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
204000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
290000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
81000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80500
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
46937000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
60162000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div></div></div></div>
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35819772
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35423105
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35795881
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35732564
CY2015Q1 xbit Lessee Leasing Arrangements Operating Leases Early Termination Right
LesseeLeasingArrangementsOperatingLeasesEarlyTerminationRight
P2Y

Files In Submission

Name View Source Status
0001171843-18-007413-index-headers.html Edgar Link pending
0001171843-18-007413-index.html Edgar Link pending
0001171843-18-007413.txt Edgar Link pending
0001171843-18-007413-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_103118p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbit-20180930.xml Edgar Link completed
xbit-20180930.xsd Edgar Link pending
xbit-20180930_cal.xml Edgar Link unprocessable
xbit-20180930_def.xml Edgar Link unprocessable
xbit-20180930_lab.xml Edgar Link unprocessable
xbit-20180930_pre.xml Edgar Link unprocessable